# TaiKun Fund

> TaiKun Fund is a VC fund backing Health Care, Medical and Pharmaceutical. See 16 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 16
- Last investment: Jan 2026
- Lead investor: 56%
- Last updated: Aug 2026
- Website: https://taikuncompanies.com/taikun-fund/

TaiKun Fund is a private equity firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 12 | 75% |
| Medical | 9 | 56% |
| Pharmaceutical | 5 | 31% |
| Hospital | 4 | 25% |
| Biotechnology | 4 | 25% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 11 | 69% |
| Series B | 2 | 13% |
| Seed | 1 | 6% |
| Angel | 1 | 6% |
| Series C | 1 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Curegene | Curegene focuses on the treatment of anti-viral diseases as well as cardiovascular and cerebrovascular diseases. The company has made strides in the development of small molecules and nucleic acid pharmaceuticals and currently possesses the most advanced targeted prodrug and nucleic acid drug technology platforms. | $42.9M | Series C | Jan 01, 2026 |  |
| QuarkMed | QuarkMed is a nuclear medicine clinical CRO service company. |  | Series A | Oct 11, 2024 |  |
| Spruce | Spruce offers quality, objective medical imaging evaluation services for clinical research, aiding medical institutions, biopharmaceutical companies, and medical device companies in drug development, product launch, and treatment effect evaluation. | $1.4M | Series A | Aug 08, 2024 |  |
| Curegene | Curegene focuses on the treatment of anti-viral diseases as well as cardiovascular and cerebrovascular diseases. The company has made strides in the development of small molecules and nucleic acid pharmaceuticals and currently possesses the most advanced targeted prodrug and nucleic acid drug technology platforms. | $14.1M | Series B | Jan 31, 2024 |  |
| Anlong Bio | Anlong Bio focuses on the research and development of nucleic acid drugs, including gene therapy, RNA drugs, and gene editing. The core team has experience in domestic and foreign scientific research, multinational pharmaceutical companies, entrepreneurship, and investment. In the fields with huge market potential, the varieties of independentintellectual property rights are developed, and most of them are at the forefront of the country. In the field of rare diseases, they use the rich resources of rare disease patients in China to actively cooperate with foreign companies.The company aims to provide various genetic medicines to fulfill the unmet medical need in China, they develop AAV gene therapies with in-house technologies from vector discoveries to manufacturing and clinical approval. |  | Series A | Jan 23, 2024 |  |
| Anovent Pharmaceutical | Anovent Pharmaceutical develops high-quality, safe, and affordable inhalation medicines for hospitals and medical institutions. |  | Series A | Jan 04, 2024 |  |
| Huanqing Medical | Huanqing Medical is a medical products manufacturing company that specializes in developing cardiovascular circulatory auxiliary products and devices for heart treatment. |  | Series A | Nov 24, 2023 |  |
| Tyligand Bioscience | Tyligand Bioscience is a biotechnology company that focuses on the discovery and development of small molecule therapeutics to help patients with cancer and autoimmune diseases. Tyligand's pharmaceuticals are designed to target and treat tumors and autoimmune disorders, enabling healthcare professionals to prescribe more effective medicine andimprove health outcomes. |  | Series A | Jul 08, 2023 |  |
| KangaBio | KangaBio is a biotech business specializing in developing novel medicines to meet unmet medical needs. It helps in developing prodrugs of immune-stimulating medicines and other multi-specific biologics to minimize toxicities and boost treatment efficacy for already established targets. | $13.9M | Seed | Jun 23, 2023 |  |
| ROBO Medical | ROBO Medical is a medical robot research and development company. |  | Series A | Jun 05, 2023 |  |

10 of 16 investments shown.

## Co-investors
- [BOHE Angel Fund](https://shizune.co/investors/profile/bohe-angel-fund) — VC Fund, 2 deals together
- [Taiyu Investment](https://shizune.co/investors/profile/taiyu-investment) — VC Fund, 2 deals together
- [Anji Maisheng](https://shizune.co/investors/profile/anji-maisheng) — VC Fund, 1 deal together
- [Betta Pharmaceuticals](https://shizune.co/investors/profile/betta-pharmaceuticals) — VC Fund, 1 deal together
- [Binjiang District Government Fund Hang Gao Investment](https://shizune.co/investors/profile/binjiang-district-government-fund-hang-gao-investment) — VC Fund, 1 deal together
- [BridgeOne Capital](https://shizune.co/investors/profile/bridgeone-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Medical Investors in China](https://shizune.co/investors/medical-investors-china)

## FAQ

### What does TaiKun Fund invest in?

TaiKun Fund invests primarily in Health Care, Medical and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did TaiKun Fund last invest?

The most recent investment recorded for TaiKun Fund closed in Jan 2026. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co